Candid Therapeutics Inc. and Epimab Biotherapeutics Inc. have entered a $1 billion research collaboration to discover and develop novel T-cell engager candidates for autoimmune indications.
Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial milestones.
Wall Street must wait until 2025 for data from the higher-dose cohort in Tenaya Therapeutics Inc.’s phase Ib/II study with gene therapy TN-201 for MYBPC3-linked hypertrophic cardiomyopathy (HCM), but shares (NASDAQ:TNYA) closed Dec. 17 at $1.41, down $1.47, or 51%, after results from the first cohort rolled out.
The potential for TL1A-targeting duvakitug to impact unmet needs of patients with ulcerative colitis (UC) and Crohn’s disease (CD), and to provide antifibrotic effects for a host of other diseases, boosted shares of Teva Pharmaceutical Industries Ltd. and Sanofi SA by 26.5% and 6.7%, respectively, as the partners released what analysts called “best-in-class” results from the phase IIb Relieve UCCD study and prepare for a phase III trial in 2025.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Accord, Arcutis, Celltrion, Checkpoint, CSL, Dermata, Eli Lilly, Galderma, GSK, Lib, Maia, Medigene, Merck, Neurocrine, Organon, Pepgen.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Abliva, Atea, Basilea, BMS, Century, Eli Lilly, Ideaya, Immatics, Innovent, Innoviva , Nimble, Outlook, Pharming, Scisparc.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ascendis, Biohaven, Corcept, Edgewise, Foghorn, Immix, Larimar, Menarini, Newamsterdam, Puretech, Reviva, Viridian.
Biopharma deal activity in November reached $29.18 billion, up from $22.29 billion in October. Year-to-date deal values have increased 3.6%, from $194.13 billion in the first 11 months of 2023 to $201.19 billion through November this year, overtaking 2023 to be the highest year on record through the month.
RSS
